CNSA-001 Safely and Effectively Reduces Phenylalanine Levels in PKU Patients, Phase 2 Trial Shows
News
Censa Pharmaceuticals’ investigational oral therapy CNSA-001 (sepiapterin) is safe and more effective than Kuvan (sapropterin dihydrochloride) in reducing the levels of phenylalanine in people with phenylketonuria (PKU), data from a Phase 2 ... Read more